Evandro de Azambuja

发表

Trastuzumab for early breast cancer: current status and future directions.

Phuong Dinh, M. Piccart-Gebhart, E. de Azambuja, 2007, Clinical advances in hematology & oncology : H&O.

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Carsten Denkert, Stefan Michiels, Christos Sotiriou, 2015, JAMA oncology.

Planning cancer control in Latin America and the Caribbean.

Richard Sullivan, Eduardo Cazap, Eduardo Rosenblatt, 2013, The Lancet. Oncology.

Molecular targeted therapies in breast cancer: where are we now?

Thierry Gil, Phuong Dinh, Fatima Cardoso, 2007, The international journal of biochemistry & cell biology.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Mitch Dowsett, Marion Procter, Brian Leyland-Jones, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dissecting the heterogeneity of triple-negative breast cancer.

Paul Ellis, Christos Sotiriou, Sherene Loi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Eileen Holmes, Patrick Flamen, Camilo Garcia, 2013, The Journal of Nuclear Medicine.

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Christos Sotiriou, Debora Fumagalli, C. Sotiriou, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving quality of life after breast cancer: dealing with symptoms.

E. de Azambuja, A. C. Pinto, Evandro de Azambuja, 2011, Maturitas.

Review: side effects of approved molecular targeted therapies in solid cancers.

Phuong Dinh, A. Awada, E. de Azambuja, 2007, The oncologist.

On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.

Lajos Pusztai, Christos Sotiriou, Stephen B. Fox, 2019, Journal of Clinical Oncology.

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

Marion Procter, Thomas Suter, R. Gelber, 2017, The New England journal of medicine.

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Stefan Michiels, Christos Sotiriou, Martine J Piccart, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER-2 as a Target for Breast Cancer Therapy

Christine Desmedt, Christos Sotiriou, C. Sotiriou, 2009, Clinical Cancer Research.

Multifactorial approach to predicting resistance to anthracyclines.

Yuan Qi, Gianluca Bontempi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.